Vector induced skewing of antibody Fc-effector functions

Background The RV144 vaccine showed a moderate efficacy of protection from HIV infection. The major immune response induced by RV144 was non-neutralizing HIV-specific antibodies (Abs), that may have potentially mediated Ab Dependent Cellular Cytotoxicity (ADCC) and/or Ab dependent Cellular Phagocytosis (ADCP). However little is known about the potential role of different vaccine regimens on inducing these types of humoral immune responses, and whether particular vaccine approaches may preferentially induce robust innate immune recruiting antibody activity that could confer more protection against infection. We therefore aimed to characterize the antibody-effector functional profiles of antibodies elicited by a number of different vaccine approaches including those induced in the: VAX003 trial (bivalent rgp120 clade B/E), RV144 (ALVAC vCP1521 + rgp120 B/E), IPCAVD001 (rAd26.ENVA.01), IAVI-C002 (MVA), IAVI-P002 (DNA + MVA) and IAVI-V001 (DNA + rAd5).